Molecules and Cells

Korean Society for Molecular and Cellular Biology (한국분자세포생물학회)
권호 표지

A Lipid-derived Endogenous Inducer of COX-2: a Bridge Between Inflammation and Oxidative Stress

  • Uchida, Koji (Graduate School of Bioagricultural Sciences, Nagoya University)
  • Received : 2008.04.30
  • Accepted : 2008.05.02
  • Published : 2008.05.31
⟨ Previous Next ⟩

Abstract

Several lines of evidence indicate that the oxidative modification of protein and the subsequent accumulation of the modified proteins have been found in cells during aging, oxidative stress, and in various pathological states including premature diseases, muscular dystrophy, rheumatoid arthritis, and atherosclerosis. The important agents that give rise to the modification of a protein may be represented by reactive aldehydic intermediates, such as ketoaldehydes, 2-alkenals and 4-hydroxy-2-alkenals. These reactive aldehydes are considered important mediators of cell damage due to their ability to covalently modify biomolecules, which can disrupt important cellular functions and can cause mutations. Furthermore, the adduction of aldehydes to apolipoprotein B in low-density lipoproteins (LDL) has been strongly implicated in the mechanism by which LDL is converted to an atherogenic form that is taken up by macrophages, leading to the formation of foam cells. During the search for an endogenous inducer of cyclooxygenase-2 (COX-2), an inducible isoform responsible for high levels of prostaglandin production during inflammation and immune responses, 4-hydroxy-2-noennal (HNE), one of the most representative lipid peroxidation product, has been identified as the potential inducer of COX-2. In addition, the following study on the molecular mechanism of the COX-2 induction by HNE has unequivocally established that a serum component, which is eventually identified to be denatured LDL, is essential for COX-2 induction. Here I review current understanding of the mechanisms by which HNE in cooperation with the serum component activates gene expression of COX-2.

Keywords

References

  1. FitzGerald, G.A. (2003). COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov. 2, 879-890 https://doi.org/10.1038/nrd1225
  2. FitzGerald, G.A., Austin, S., Egan, K., Cheng, Y., and Pratico, D. (2000). Cyclo-oxygenase products and atherothrombosis. Ann. Med. 32, 21-26
  3. Gimbrone, M.A. Jr., Topper, J.N., Nagel, T., Anderson, K.R., and Garcia-Cardena, G. (2000). Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann. N.Y. Acad. Sci. 902, 230-239 https://doi.org/10.1111/j.1749-6632.2000.tb06318.x
  4. Glass, C.K., and Witztum, J.L. (2001). Atherosclerosis. The road ahead. Cell 104, 503-516 https://doi.org/10.1016/S0092-8674(01)00238-0
  5. Huang, D., Jang, B.C., Yu, G., and Boudreau, M. (1997). Expression of mitogen-inducible cyclooxygenase induced by lipopolysaccharide: mediation through both mitogen-activated protein kinase and NF-${\kappa}B$ signaling pathways in macrophages. Biochem. Pharmacol. 54, 87-96 https://doi.org/10.1016/S0006-2952(97)00154-8
  6. Ishii, T., Itoh, K., Ruiz, E., Leake, D.S., Unoki, H., Yamamoto, M., and Mann, G.E. (2004). Role of Nrf2 in the regulation of CD36 and stress protein expression in murine macrophages: activation by oxidatively modified LDL and 4-hydroxynonenal. Circ. Res. 94, 609-616 https://doi.org/10.1161/01.RES.0000119171.44657.45
  7. Kanayama, M., Yamaguchi, S., Shibata, T., Shibata, N., Kobayashi, M., Nagai, R., Arai, H., Takahashi, K., and Uchida, K. (2007). Identification of a serum component that regulates cyclooxygenase-2 gene expression in cooperation with 4- hydroxy-2-nonenal. J. Biol. Chem. 282, 24166-24174 https://doi.org/10.1074/jbc.M703212200
  8. Koki, A., Khan, N.K., Woerner, B.M., Dannenberg, A.J., Olson, L., Seibert, K., Edwards, D., Hardy, M., Isakson, P., and Masferrer, J.L. (2002). Cyclooxygenase-2 in human pathological disease. Adv. Exp. Med. Biol. 507, 177-184
  9. Kumagai, T., Kawamoto, Y., Nakamura, Y., Hatayama, I., Satoh, K., Osawa, T., and Uchida, K. (2000). 4-Hydroxy-2-nonenal, the end product of lipid peroxidation, is a specific inducer of cyclooxygenase-2 gene expression. Biochem. Biophys. Res. Commun. 273, 437-771 https://doi.org/10.1006/bbrc.2000.2967
  10. Kumagai, T., Nakamura, Y., Osawa, T., and Uchida, K. (2002). Role of p38 mitogen-activated protein kinase in the 4- hydroxy-2-nonenal-induced cyclooxygenase-2 expression. Arch. Biochem. Biophys. 397, 240-245 https://doi.org/10.1006/abbi.2001.2601
  11. Kumagai, T., Matsukawa, N., Kaneko, Y., Kusumi, Y., Mitsumata, M., and Uchida, K. (2004). A lipid peroxidationderived inflammatory mediator: Identification of 4-hydroxy- 2-nonenal as a potential inducer of cyclooxygenase-2 in macrophages. J. Biol. Chem. 279, 48389-48396 https://doi.org/10.1074/jbc.M409935200
  12. Nagy, L., Tontonoz, P., Alvarez, J.G., Chen, H., and Evans, R.M. (1998). Oxidized LDL regulates macrophage gene expression through ligand activation of PPARg. Cell 93, 229-240 https://doi.org/10.1016/S0092-8674(00)81574-3
  13. Podrez, E.A., Poliakov, E., Shen, Z., Zhang, R., Deng, Y., Sun, M., Finton, P.J., Shan, L., Gugiu, B., Fox, P.L., et al. (2002). Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J. Biol. Chem. 277, 38503-38516 https://doi.org/10.1074/jbc.M203318200
  14. Quinn, M.T., Parthasarathy, S., Fong, L.G., and Steinberg, D. (1987). Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc. Natl. Acad. Sci. USA 84, 2995-2998
  15. Reddy, S.T., Wadleigh D.J., and Herschman, H.R. (2000). Transcriptional regulation of the cyclooxygenase-2 gene in activated mast cells. J. Biol. Chem. 275, 3107-3113 https://doi.org/10.1074/jbc.275.5.3107
  16. Smith, W.L., and Langenbach, R. (2001). Why there are two cyclooxygenase isozymes. J. Clin. Invest. 107, 1491-1495 https://doi.org/10.1172/JCI13271
  17. Sevanian, A., Hwang, J., Hodis, H.N., Cazzolato, G., Avogaro, P., and Bittolo-Bon, G. (1996). Contribution of an in vivo oxidized LDL to LDL oxidation and its association with dense LDL subpopulations. Arterioscler. Thromb. 16, 784-793 https://doi.org/10.1161/01.ATV.16.6.784
  18. Sevanian, A., Bittolo-Bon, G., Cazzolato, G., Hodis, H., Hwang, J., Zamburlini, A., Maiorino, M., and Ursini, F. (1997). LDLis a lipid hydroperoxide-enriched circulating lipoprotein. J. Lipid Res. 38, 419-428
  19. Sevanian, A., Asatryan, L., and Ziouzenkova, O. (1999). Low density lipoprotein (LDL) modification: basic concepts and relationship to atherosclerosis. Blood Purif. 17, 66-78 https://doi.org/10.1159/000014378
  20. Steinberg, D. (1995). Role of oxidized LDL and antioxidants in atherosclerosis. Adv. Exp. Med. Biol. 369, 39-48
  21. Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C., and Witztum, J.L. (1989). Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320, 915-924 https://doi.org/10.1056/NEJM198904063201407
  22. Suc, I., Meilhac, O., Lajoie-Mazenc, I., Vandaele, J., Jurgens, G., Salvayre, R., and Negre-Salvayre, A. (1998). Activation of EGF receptor by oxidized LDL. FASEB J. 12, 665-671 https://doi.org/10.1096/fasebj.12.9.665
  23. Uchida, K. (2003). 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog. Lipid Res. 42, 318-343 https://doi.org/10.1016/S0163-7827(03)00014-6
  24. Ziouzenkova, O., Asatryan, L., Akmal, M., Tetta, C., Wratten, M.-L., Heinecke, J., and Sevanian, A. (1999). Cross-linking between low density lipoprotein apoB and hemoglobin mediates conversion to electronegative LDL- during the ex-vivo blood circulation. J. Biol. Chem. 274, 18916-18924 https://doi.org/10.1074/jbc.274.27.18916